Creator Fund’s Post

🚀 Very Exciting Stealth Launch! 🚀 Mirador Therapeutics, led by former Executives from Prometheus Biosciences, Inc., including Mark Mckenna, Olivier Laurent, and Allison Luo, has launched from stealth with a staggering $400 million. Based in San Diego, Mirador will focus on precision medicines for immuno-inflammatory and fibrotic diseases 💊. The funding was led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount Partners, and support from an impressive lineup of further investors 💸💸 Mirador's innovative development engine, Mirador360, combines human genetics with data science to create new precision medicines. Their goal? To revolutionize treatment options for patients through accelerated and precise drug development! 🌟Exciting times lie ahead for Mirador!🌟 #PrecisionMedicine #Biotech #Innovation #Stealthmode #Venturefunding #pharma #Fibroticdisease #Autoimmune #immunoinflammatory

It´s strategic investment Friday.......IPO edition. Well, the new year fireworks keep blazing in the biotech IPO sky, and the latest rocket to take off is none other than Kyverna Therapeutics. These guys are gunning for public market fuel to propel their two lead CD19 #CAR-T therapies through the clinic - KYV-101 for #autoimmune diseases like lupus nephritis, MS, and myasthenia gravis, and KYV-201, an "off-the-shelf" version developed with Intellia Therapeutics, Inc. Their KYV-101 aims at B cells, those little autoimmune mischief-makers, with the ambition of not just zapping them, but potentially "resetting" them to play nice. That's a whole new level of cellular diplomacy if you ask me. They've got some heavy hitters in their corner. Gilead's been backing them since Day One, and last August they snagged $145 million from Bain Capital Life Sciences and others. They're even partnered with Verily, Alphabet's precision health and Biotech arm, to use its state-of-the-art immune mapping platform (Immune Profiler) to elucidate biomarkers of treatment response in autoimmune patients treated with Kyverna’s KYV-101 Of course, the CAR-T space is crowded, and competition is fierce. But Kyverna's got a well-rounded pipeline, with research programs targeting IBD and beyond, and ambitious plans to venture into regulatory T cells and novel humanized CAR constructs. This is no one-trick pony. So, will Kyverna's IPO blast off to Mars or crash and burn? It's still early days, folks, but with the IPO window "gradually reopening" as PwC says, and with Alto Neuroscience, Metagenomi, CG Oncology, and ArriVent Biopharma already lighting up the launchpad, I wouldn't bet against these CAR-T contenders. My advice? Buckle up, biotech fans, it's gonna be a wild ride. #biotech #IPO #CAR-T #autoimmune #precisionmedicine #investmentbanking #lifescience #investment #biotech #investor #market #business #PE #pharmaceutical #health #vc #capital _________________________________________________________________________________ Have you enjoyed this? Recommend Repost ♻️ if you find it useful Follow me, hit the 🔔 Adrian Rubstein

Biotech IPOs are HOT right now but, WHY? Let me shed some light on this red-hot IPO revival. It's a confluence of factors, like a perfectly timed clinical trial: 1. Innovation on Fire: The science is cooking! Breakthroughs in gene editing (think CRISPR), gene therapy, and mRNA technology are fueling a pipeline of revolutionary drugs and therapies. Investors are chasing the next blockbuster, and early-stage biotechs with promising pipelines are attracting major attention. Remember Moderna's meteoric rise on the back of its COVID-19 mRNA vaccine? 2. Big Pharma's Shopping Spree: The big boys are feeling flush and hungry. With M&A activity at an all-time high, established pharmaceutical companies are on the prowl for promising new assets. This creates a feeding frenzy for innovative biotechs, driving up valuations and making IPOs an attractive exit strategy. Take, for example, Amgen's recent $3.9 billion acquisition of Horizon Therapeutics, a testament to the value they see in innovative biotech players. 3. Specialized Investors on the Prowl: Hedge funds and dedicated biotech investment firms are piling in. This influx of specialized capital fuels the IPO fire, providing the critical mass of investors needed to make these offerings successful. Take a look at ARCH Venture Partners, a leading biotech investor, who raised a record-breaking $1.8 billion fund last year and looking to raise $ 3 billion this year. 4. Regulatory Tailwinds: The regulatory environment is getting more simplified, especially when it comes to fields like gene editing. For potential biotechs, this lowers barriers to medication development and commercialization, resulting in a smoother and more predictable road to market. But hold on, it's not all sunshine and rainbows: 1. The Hype Cycle: Remember, biotech is inherently risky. Many early-stage companies don't make it to the finish line. Investors need to be cautious not to get caught up in the hype and carefully evaluate the underlying science and business fundamentals. 2. Valuation Concerns: With valuations soaring, a bubble is likely to form. Investors need to be disciplined and ensure they're paying a fair price for the potential return. So, is the biotech IPO revival here to stay? It's too soon to say with certainty. But the future is undoubtedly bright given the combination of the previously listed variables. This IPO boom may continue if innovation keeps growing, big pharma keeps shopping, and investors maintain their self-control. 𝐈𝐟 𝐲𝐨𝐮 𝐚𝐫𝐞 𝐟𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐢𝐧𝐠 𝐨𝐫 𝐝𝐮𝐫𝐢𝐧𝐠 𝐌&𝐀 𝐚𝐧𝐝 𝐰𝐚𝐧𝐭 𝐭𝐨 𝐤𝐧𝐨𝐰 𝐭𝐡𝐞 𝐯𝐚𝐥𝐮𝐞 𝐨𝐟 𝐲𝐨𝐮𝐫 𝐚𝐬𝐬𝐞𝐭 𝐨𝐫 𝐜𝐨𝐦𝐩𝐚𝐧𝐲, 𝐛𝐨𝐨𝐤 𝐚 𝐦𝐞𝐞𝐭𝐢𝐧𝐠 𝐚𝐧𝐝 𝐰𝐞 𝐰𝐢𝐥𝐥 𝐭𝐫𝐲 𝐭𝐨 𝐡𝐞𝐥𝐩 𝐲𝐨𝐮. Rohan Gidvani https://lnkd.in/eN6-8cnt #genetherapy #lifescience #invest #investor #investment #VC #pharmaceutical #IPO #Biotech #biotechnology #company #CEO

As the landscape of biotech innovation perpetually evolves, a noteworthy stride has been made by Contineum Therapeutics. It's a moment of elevation—Contineum's disclosure of their IPO plans could be a formidable advance for treatments in neurological and inflammatory ailments. This forward leap doesn't occur in isolation. With a legacy intertwined through Versant Ventures' fertile innovation soil, Contineum germinated from the enduring tree of Inception Sciences. Notably, Versant's keen eye for nascent potential bore fruit when Roche embraced Inception 5 six years past, propelling forward a mission to heal the neurological fabric sundered by disease. With private funding approximating £194 million, Contineum's arsenal of small molecule medicines target afflictions from the enigmatic depths of multiple sclerosis to the perplexing realms of idiopathic pulmonary fibrosis and the sombre tides of depression. These prospects aren't mere statistical entries; they carry the hope for life-altering therapies, with one proudly owned candidate coursing through Phase 1 trials and another, in alliance with Johnson & Johnson, forging ahead into mid-stage evaluation. Here's a fraction of the puzzle often overlooked: As Contineum stands on the cusp of public trading, we find at its core an intellectual symphony—a collaboration of Versant, academic pioneers, and seasoned executives harmonizing to orchestrate 'neuro-regeneration'. The beacon lit by Contineum is but a reflection of a broader resurgence in biotech IPOs. While February's hiatus whispers of caution, March resounds with renewed vigour as Contineum became the fourth biotech prodigy to announce IPO intentions. Beyond funding, it's a testament to resilience and innovation underpinning the sector's growth narrative in recent years. Amidst this symphony, Contineum's pitch soars, seeking differentiation in a choir of rivals like Bristol Myers Squibb and Structure Therapeutics, each vying for mastery over similar maladies. Yet, their claim of distinction is no mere boast; preclinical trials hint at an edge—a difference that could define the future course for patients ensnared by these conditions. #Biotech #IPO #Innovation

Stories making headlines today in the biopharma industry: The biotech industry experienced a noteworthy resurgence in H1 2024, with 50 startups closing nine-figure funding rounds. Echoing the peaks of 2020 and 2021, by March 20, 21 megarounds had been announced, with momentum increasing into Q2. Most investments are directed at companies with clinical trials ongoing, signaling forthcoming data or risk reduction. Of the 50 funded, 15 had not commenced clinical trials. Flagship Pioneering, renowned for its role in creating Moderna, is seeking to expand its eighth fund by $500 million, aiming for $3.5 billion. Backed by major entities like Massachusetts Pension Reserves Investment Management and Texas Municipal Retirement System, this increase underscores investor confidence in Flagship's influence in biotech. Oncology-focused Apollomics announced strategic cost-cutting and leadership changes. Co-founder Sanjeev Redkar and CMO Peony Yu will step down in August but remain as consultants. Apollomics will refine its Phase 2 trial for vebreltinib, now focusing on non-small cell lung cancer with Met amplification. Pfizer appointed Cyrus Taraporevala, former State Street Global Advisors CEO, to its board as it prepares for Q2 earnings and furthers cost reductions. Taraporevala also holds board positions at Shell and Bridgepoint Group. GSK is investing €400 million to assume full rights to influenza and Covid vaccine candidates from its CureVac collaboration. GSK is terminating several other collaborative programs, prompting CureVac to downsize by 30% to focus on high-value mRNA pipelines as stated by CEO Alexander Zehnder. Beacon Therapeutics raised $170 million to advance its gene therapy for X-linked retinitis pigmentosa, challenging Johnson & Johnson's late-stage trial for botaretigene sparoparvovec. This financing round marks the biotech industry's 50th nine-figure round of 2024, underscoring sustained investor interest. Eli Lilly achieved approval for its Alzheimer’s drug, marking a significant victory in their battle against the disease. This approval validates years of research and stands to provide new treatment options for Alzheimer's patients. Lastly, Dupixent, co-developed by Sanofi and Regeneron, gained EU approval for treating COPD. This advancement precedes an FDA decision and enhances treatment options for chronic respiratory condition patients. #pharma #biotech #topstories #biodatastudio

Passkey Therapeutics is launching out of stealth—with a Breakout Ventures-led Series Seed—to target complex diseases like cancer and metabolic disorders with multifunctional therapeutics!   𝐍𝐞𝐰𝐬 𝐚𝐭 𝐚 𝐠𝐥𝐚𝐧𝐜𝐞:  🧬 Combining computational power and experimental validation, Passkey Therapeutics designs Synergistic Multifunctional Therapeutics (SMThs) to target multiple proteins at once. This will be a game-changer, especially for complex diseases that arise from multiple proteins.     ⭐ Bruce Beutel and his world-class team have decades of success in biotech R&D and company building. Leadership includes Co-founder and CTO William Chen, COO Peter Dandliker, and Co-founder and SVP of Computational Chemistry Soumya Ray.    💸 We’re joined in the Series Seed round by founding investors Innovation Endeavors and Bison Ventures. Additional participants include Wireframe Ventures, Alexandria Real Estate Equities, Inc. Venture Investments, and GRIDS Capital.    𝐑𝐞𝐚𝐝 𝐰𝐡𝐲 Breakout Ventures 𝐛𝐞𝐥𝐢𝐞𝐯𝐞𝐬 𝐒𝐌𝐓𝐡𝐬 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐢𝐧𝐞𝐯𝐢𝐭𝐚𝐛𝐥𝐞 𝐜𝐮𝐥𝐦𝐢𝐧𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐝𝐫𝐮𝐠 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐢𝐧 Dana Watt, PhD'𝐬 𝐖𝐡𝐲 𝐖𝐞 𝐈𝐧𝐯𝐞𝐬𝐭𝐞𝐝: https://lnkd.in/diCkAJBU 

Modality matters as ADC’s& Radioisotope ligands clinical assets are of great interest to investors. Cell& Gene therapy assets do not hold the same interest among investors with questions on manufacturing& scalability being still touted as issues of concern. London (UK) has emerged as an AI-Biotech hub with the best companies among start-up’s& Big pharma leading to greater collaboration. China’s Biotech sector is now on par with western countries providing late-stage clinical ADC assets which investors have mopped up. Genmab CEO in a recent Financial Times article, described China’s Biotech strides as “mindbogglingly impressive innovation.”

Thanks for sharing this article Russ! So many innovative companies on the list. The future looks bright for the life sciences. #startup #innovation #phase 1 #commercialization

Biotech IPO Surge: Three Startups Raise Over $700M Three biotechnology companies recently made headlines by collectively raising more than $700 million in IPOs, marking a surge in activity following a relatively quiet summer in the biotech space. Leading the way was Bicara Therapeutics, which secured $315 million, the third-largest IPO in the sector this year, focusing on cancer treatments. Zenas BioPharma, specializing in autoimmune diseases, followed closely with $225 million, while MBX Biosciences raised $163 million for its work on metabolic conditions, including obesity. This wave of IPOs is notable, especially considering the slower pace of public offerings in recent years. While some biotechs struggle with market conditions, later-stage companies like these, with drugs already in human trials, seem to have found their stride. Their success signals potential momentum for future biotech IPOs. Exchange Listing has a dedicated life science group and is committed to the sector with the applicable resources to support small-, micro-cap life science IPOs for companies interested in going public.

Biopharma Funding & Emerging Start-Up Update June 10-14th ‘24 Newly launched biotechnology startups w/ ADC pipelines and more funding events… Get this weekly • https://lnkd.in/gDGtEEyy – 𝐏𝐫𝐢𝐯𝐚𝐭𝐞 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 – Santa Ana Bio, Inc. 💸  Launched with $168 million in funding from combined Series A and B rounds to advance its precision immunology pipeline. The lead asset is SAB03, targeting autoimmune and inflammatory diseases, clinical trials are planned for 2025. Amber Therapeutics 💸  Closed $100M Series A funding led by New Enterprise Associates (NEA) to advance Amber-UI for Mixed Urinary Incontinence (MUI) through pilot and pivotal studies toward regulatory approval in the US. Alzheon, Inc. | Preserving Future Memories 💸  Raised $100M in Series E round led by Alerce Medical Technology Partners to fund the completion of its Ph 3 study for lead candidate (ALZ-801) for Alzheimer's disease (AD) later this year. Adcytherix 💸  Launched with €30M in seed funding led by Pontifax to develop next-generation novel ADCs for the treatment of different diseases such as cancer. Moleculent 💸  Launched with $26M Series A financing led by ARCH Venture Partners to study cell-to-cell interaction.  – 𝐏𝐨𝐬𝐭-𝐈𝐏𝐎/𝐏𝐮𝐛𝐥𝐢𝐜 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 – Avidity Biosciences, Inc. 🏦  Announced pricing of $400.9M public offering. Ultragenyx 🏦  Announced pricing of $350M public offering. Abeona Therapeutics 🏦  Filed for $300M securities offering to fund BLA resubmission and pz-cel commercialization Disc Medicine 🏦  Announced  $178M public offering. Replimune 🏦  Announced $100M private placement financing to support a potential launch of RP1. At BiopharmIQ by Amp we maintain biopharma data to help with your sales/BD activities. 📰 Each week we share clinical/regulatory/funding news in an easy-to-digest format. #biotech #biopharma